Aerovate Therapeutics, Inc.
Net SellingAVTE·US·🇺🇸 US
14%buys·86%sales
634 transactions$280.8MTotal buys·23 buys
$13.8MTotal sells·138 sells
4040 insiders
Last: Oct 6, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Oct 6, 25 | Fairmount Healthcare Co-Invest IV L.P. | Grant | $7.8M | |
| Oct 6, 25 | Harwin Peter Evan | Grant | $7.8M | |
| Oct 6, 25 | Kiselak Tomas | Grant | $7.8M | |
| Oct 6, 25 | Fairmount Funds Management LLC | Grant | $7.8M | |
| Oct 6, 25 | Fairmount Healthcare Fund II L.P. | Grant | $7.8M | |
| Oct 6, 25 | Fairmount Healthcare Co-Invest IV L.P. | Grant | $12.2M | |
| Oct 6, 25 | Harwin Peter Evan | Grant | $12.2M | |
| Oct 6, 25 | Kiselak Tomas | Grant | $12.2M | |
| Oct 6, 25 | Fairmount Funds Management LLC | Grant | $12.2M | |
| Oct 6, 25 | Fairmount Healthcare Fund II L.P. | Grant | $12.2M |
Aerovate Therapeutics, Inc. (AVTE) has recorded 634 insider transactions from 40 insiders. Total insider buying volume stands at $280.8M, while total selling volume is $13.8M. Overall insider sentiment is bearish (86% sales).
Aerovate Therapeutics, Inc. (AVTE) has recorded 634 insider operations, including 23 open-market purchases ($280.8M), 138 sales ($13.8M) and 473 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (86% sales).
Aerovate Therapeutics, Inc. shows moderate insider activity with 4 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are NOYES TIMOTHY P (CEO), Frohlich Tom (CEO) & Dahms Bradford D. (CFO), with respectively 80, 45, 13 transactions.
Across all 634 recorded transactions, the breakdown by type is: exercise (356, 56%), sales (138, 22%), grant (111, 18%), buys (23, 4%), other (6, 1%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Aerovate Therapeutics, Inc. has recorded 634 insider operations in total, including 23 open-market purchases ($280.8M), 138 sales ($13.8M) and 473 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on October 6, 2025.
Insiders at Aerovate Therapeutics, Inc. are currently net sellers, with 14% purchases and 86% sales across all reported transactions. Total buy volume is $280.8M versus $13.8M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 40 insiders at Aerovate Therapeutics, Inc. (AVTE). NOYES TIMOTHY P (CEO, 80 tx), Frohlich Tom (CEO, 45 tx), Dahms Bradford D. (CFO, 13 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for AVTE is bearish, based on a 14% buy ratio across 161 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Aerovate Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.